Mesenchymal Stem Cell Conditioned Medium as Good as Methyl Prednisolone in Decreasing Levels of Interleukin 10 and The Degree of Pulmonary Vasculitis in Lupus Mice

Authors

  • Nurhasan Agung Prabowo Division of Rheumatology, Department of Internal Medicine, Dr.Moewardi General Hospital, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia
  • Zainal Arifin Adnan Division of Rheumatology, Department of Internal Medicine, Dr.Moewardi General Hospital, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia
  • Arief Nurudhin Division of Rheumatology, Department of Internal Medicine, Dr.Moewardi General Hospital, Faculty of Medicine, Surakarta, Indonesia
  • Yulyani Werdiningsih Division of Rheumatology, Department of Internal Medicine, Dr.Moewardi General Hospital, Faculty of Medicine, Surakarta, Indonesia
  • Kukuh Prasetyo Division of Rheumatology, Department of Internal Medicine, Dr.Moewardi General Hospital, Faculty of Medicine, Sebelas Maret University, Surakarta, Indonesia

DOI:

https://doi.org/10.3329/bjms.v20i2.51560

Keywords:

Mesenchymal stem cell conditioned medium, methyl prednisolone, interleukin 10, pulmonary vasculitis, lupus mice

Abstract

Background: Systemic lupus erythematosus is a chronic autoimmune disease that affects target organs. mesenchymal stem cell conditioned medium has immunosuppressive, anti-inflammatory, and immunoregulatory properties in lupus. Methyl prednisolone is a standard drug for lupus with immunosuppressive and anti-inflammatory properties. This study aims to compare the therapeutic effect of mesenchymal stem cell conditioned medium administration compared to methyl prednisolone on interleukin 10 levels and the degree of pulmonary vasculitis of lupus mice.

Methods: The subjects were 24 female mice of Mus musculus Balb/C strain, which were categorized into 4 groups of 8 mice, i.e. the control group receiving 0.5 cc of 0.9% NaCl injection and placebo, the lupus group receiving 0.5 cc of pristane injection and placebo, and the treatment mesenchymal stem cell conditioned medium group receiving 0.5 cc pristane injection and mesenchymal stem cell conditioned medium 0,5 cc, and methylprednisolone group receiving 0,5 cc pristiane injection and methylprednisolone p.o 1,5 mg/kgbodyweight. After 24 days the mice were terminated and kidney and blood samples were taken. Statistical analysis was performed using ANOVA test followed by independent T-test. The p value was considered significant when the p < 0.05.

Results: The study showed that there was no difference on the levels of interleukin level10 among mesenchymal stem cell conditioned medium goup and methyl prednisolone group (CM = 5,94 ± 2,49 pg/mL, mp = 5,86+1,73 pg/mL; p = 1) and the degree of pulmonary vasculitis (CM= 1,94 ± 0,25, MP=1,89+ 0,11 pg/ml; p = 0.667). Mesenchymal stem cell conditioned medium as good as methyl prednisolone in decreasing levels of interleukin 10 and the degree of pulmonary vasculitis in lupus mice.

Conclusion: Mesenchymal stem cell conditioned medium as good as methyl prednisolone in decreasing levels of interleukin 10 and the degree of pulmonary vasculitis in lupus mice

Bangladesh Journal of Medical Science Vol.20(2) 2021 p.426-430

Downloads

Download data is not yet available.
Abstract
113
PDF
46

Downloads

Published

2021-02-01

How to Cite

Prabowo, N. A., Adnan, Z. A., Nurudhin, A., Werdiningsih, Y., & Prasetyo, K. (2021). Mesenchymal Stem Cell Conditioned Medium as Good as Methyl Prednisolone in Decreasing Levels of Interleukin 10 and The Degree of Pulmonary Vasculitis in Lupus Mice. Bangladesh Journal of Medical Science, 20(2), 426–430. https://doi.org/10.3329/bjms.v20i2.51560

Issue

Vol. 20 No. 2 (2021)

Section

Original Articles

License

Authors who publish in the Bangladesh Journal of Medical Science agree to the following terms that:

  1. Authors retain copyright and grant Bangladesh Journal of Medical Science the right of first publication of the work.

  2. Creative Commons Licence
    Articles in Bangladesh Journal of Medical Science are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0.This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
  3. Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  4. Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.